VASO Corp Annual Report - How They Did This Year

I’m writing this guide to help you understand VASO Corp’s performance this past year. My goal is to cut through the corporate jargon so you can decide if this company fits your investment goals.

1. The Big Picture

VASO Corp operates through three main business areas:

• Professional Sales: This is their "middleman" business. They are the exclusive sales representative for GE HealthCare, selling diagnostic imaging and ultrasound equipment to U.S. medical providers. This is their primary source of income.
• Medical Equipment: This is their "homegrown" side. They design, make, and sell cardiovascular diagnostic products, such as VasoView and VasoGuard, with factories in China and the U.S.
• NetWolves: This business provides IT security, cloud infrastructure, and network connectivity for companies. It generates steady, recurring monthly income.

2. The Numbers: A Mixed Bag

VASO reported a $1.57 million profit in 2025, up 65% from $951,000 in 2024. It is important to note that a significant portion of this profit came from a one-time $6.5 million gain from selling their healthcare IT division.

• Revenue: Total sales reached $89.1 million, a 2.7% increase from $86.7 million in 2024.
• The "Middleman" Success: The GE HealthCare partnership is their strongest performer. Revenue here grew nearly 7% to $44.2 million, making up about half of the company’s total revenue.
• Operating Costs: The company had an operating loss of $2.9 million, meaning day-to-day costs exceeded income. This was largely due to a $4.6 million charge related to the healthcare IT division, reflecting that the unit's book value was adjusted downward.

3. Wins and Challenges

• The Big Win: They extended their exclusive sales agreement with GE HealthCare through 2030, securing their most important revenue stream for the next five years.
• The Big Change: They sold their healthcare IT division in late 2025 for $7.2 million. This allows management to focus on their core medical sales and equipment manufacturing.
• The "Near Miss": They canceled their merger with Achari Ventures Corp in early 2025, choosing to remain an independent public company.

4. The Risks

• Reliance on a Giant: Half of their revenue depends on the GE HealthCare agreement. If that relationship ends, the company’s financial health would be at serious risk.
• Manufacturing & Geopolitics: Manufacturing in China exposes the company to tariffs, trade policy shifts, potential intellectual property theft, and supply chain disruptions.
• Operating Costs: Selling and administrative expenses rose 6.6% to $24.1 million, driven by hiring more sales staff and higher professional fees.
• "Anti-Takeover" Rules: The company uses structures that make it difficult for outside investors to force a change in management or strategy, even if the stock price performs poorly.

5. What’s Next

VASO is currently streamlining. By selling their IT business and focusing on medical sales, they aim to improve efficiency. They also plan to grow their cloud-based heart-monitoring software, which provides higher-margin, recurring subscription fees compared to one-time hardware sales. Management intends to use the GE partnership to cross-sell these tools to their existing clients.

Investor Takeaway: VASO is currently a company in transition. The long-term extension of the GE HealthCare contract provides a solid foundation, but the company’s ability to turn a profit from its core operations—rather than one-time asset sales—will be the key indicator of success in the coming year. Watch their operating expenses closely to see if their recent hiring and restructuring efforts translate into actual growth.